A prospective cohort study by Xie et al. demonstrated improved breast cancer-specific survival (BCCS) with adjuvant ET, most notably with aromatase inhibitors (AIs) or sequential tamoxifen followed by AIs, even among patients with low ER-positive, HER2-positive disease [20]. This evidence concerns the gene ERBB2 and breast carcinoma.